Medicamen Biotech Ltd
NSE: MEDICAMEQ BSE: 531146
₹223.30
(-6.49%)
Thu, 02 Apr 2026, 07:20 pm
Market Cap3.05B
PE Ratio31.60
Dividend0.42
Health Technology
Pharmaceuticals: Major
24.5KMedicamen Biotech Analysis
dividend
- Medicamen Biotech is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Medicamen Biotech's dividends as it is not paying a notable one for India.
- Medicamen Biotech is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Medicamen Biotech's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Medicamen Biotech's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Medicamen Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Medicamen Biotech is profitable, therefore cash runway is not a concern.
- Medicamen Biotech is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (82.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 20x debt.
- Medicamen Biotech's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (95% vs 4.5% today).
- Medicamen Biotech earns more interest than it pays, coverage of interest payments is not a concern.
- Medicamen Biotech's level of debt (4.5%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Medicamen Biotech board of directors is about average.
- Rajesh's remuneration is higher than average for companies of similar size in India.
misc
- Medicamen Biotech is not covered by any analysts.
- Medicamen Biotech has significant price volatility in the past 3 months.
past
- Medicamen Biotech has delivered over 20% year on year earnings growth in the past 5 years.
- Medicamen Biotech used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Medicamen Biotech's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (23.4% vs 22.7%).
- Medicamen Biotech's 1-year earnings growth is less than its 5-year average (23.4% vs 50.3%)
- Medicamen Biotech's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Medicamen Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- BSE:531146 is up 19.7% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:531146 is up 19.7% outperforming the market in India which returned 8% over the past month.
- Medicamen Biotech's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Medicamen Biotech's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Medicamen Biotech is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Medicamen Biotech is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Medicamen Biotech is overvalued based on earnings compared to the India market.
- 531146 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 531146 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800